
ABSTRACT Aim The Rotterdam Diabetic Foot (RDF) Test Battery was developed to assess sensory function and predict the risk of diabetic foot ulceration and falls. We evaluated its interobserver reliability in patients with diabetic sensorimotor polyneuropathy. Methods The RDF Test Batteries include a continuous and dichotomous 39‐item scale and a shorter dichotomous 13‐item scale. The 39‐item test battery was administered by two investigators, and the 13‐item test battery by five investigators with varying experience. Percentage agreement, Cohen's kappa coefficient ( κ ) and intraclass correlation coefficient (ICC) were calculated, including agreement in ulcer risk classification based on predefined cut‐off values derived from the 39‐item and 13‐item test battery sum scores; incident ulcer outcomes were not collected. Results The continuous 39‐item test battery ( n = 36 test batteries) showed low to high exact agreement (33.9%–100%), poor item‐level ICCs (0.04–0.19), and small median between‐observer differences. Dichotomous 39‐item ( n = 56) and 13‐item test batteries ( n = 310) showed low percentage agreement (42.9% and 47.1%) but good reliability (ICC 0.83, 95% CI: 0.67–0.92 and 0.80, 95% CI: 0.73–0.85). Cut‐off based classification of ulcer risk of the 39‐item and 13‐item test batteries showed acceptable to high agreement (96.4% and 87.1%) and substantial reliability ( κ = 0.67 and 0.73, both p < 0.001). Conclusion Both instruments showed good reproducibility in sensory staging, although this varied using scoring approach and analysis level. The dichotomous test batteries showed good reliability at the sum‐score level, whereas exact agreement for the continuous 39‐item test battery and reliability of several individual items were limited. Clinical use and ulcer risk classification require further evaluation before routine implementation.
ABSTRACT Aims To evaluate the effectiveness and treatment patterns of once‐weekly semaglutide 2.4 mg in South Korean adults with overweight or obesity in real‐world practice. Materials and Methods This multicenter retrospective study analysed electronic medical records from 17 centres in South Korea. Included were adults (≥ 19 years) with BMI ≥ 25 kg/m 2 , or ≥ 23 kg/m 2 with obesity‐related comorbidities. Primary endpoints were changes in body weight at 3, 6, 9, and 12 months. Secondary outcomes included body composition, categorical weight loss, cardiometabolic changes, treatment persistence, safety, and changes in liver function. Results Among 1160 patients (40.9% with prior obesity medications), semaglutide treatment induced progressive weight reduction (−5.85%, −9.55%, −11.43%, and −13.16% at 3, 6, 9, and 12 months). Greater reduction occurred in women, younger patients, and those without T2D or prior obesity medication. By 6 months, cardiometabolic, liver function, and body composition parameters improved, with preferential loss of fat over lean mass (all p < 0.001). Starting doses varied across patients (0.25 mg, 55.9%; 0.5 mg, 30.4%; 1.0 mg, 11.9%), with rapid dose escalation reaching the maintenance dose (2.4 mg) in a mean of 3.52 months, reflecting individualised real‐world dosing. Mean treatment duration was 4.9 months. Adverse events, predominantly transient gastrointestinal symptoms, occurred in approximately 22% of patients. Conclusions Semaglutide 2.4 mg achieved substantial weight loss in South Korean adults with overweight or obesity. Weight reduction was comparable to the STEP 6 trial despite shorter follow‐up (4.9 months), substantial prior obesity medication exposure, and accelerated dose escalation, supporting robust real‐world effectiveness.
ABSTRACT Aims Physical activity is central to the management of type 1 diabetes, yet diabetes‐specific barriers may reduce habitual activity. We systematically reviewed and meta‐analysed studies comparing physical activity and sedentary behaviour in adults with type 1 diabetes and adults without diabetes. Material and Methods MEDLINE, Embase, and SPORTDiscus were searched from inception to 24 July 2026. Random‐effects models were used to pool standardised mean differences for continuous outcomes and odds ratios (OR) for meeting physical activity recommendations or study‐defined active criteria. Results Sixteen publications representing 14 independent cohorts and 3335 participants were included (54.2% females). Adults with type 1 diabetes had lower total physical activity than adults without diabetes (12 studies; Hedges g = −0.13; 95% confidence interval, −0.22 to −0.05; p = 0.001), with no detected heterogeneity. They also had lower estimated odds of meeting a physical activity criterion, although the association was not statistically significant (4 studies; OR = 0.77; 95% confidence interval, 0.58–1.02; p = 0.066). Mean age, diabetes duration and glycated haemoglobin were not associated with between‐group differences in total physical activity. Data were insufficient to pool sedentary behaviour, steps or intensity‐specific outcomes. Conclusions Adults with type 1 diabetes engage in slightly less total physical activity than adults without diabetes, although evidence regarding adherence to physical activity recommendations remains inconclusive. The absence of population‐based studies limits the generalisability of these findings and highlights the need for representative studies using standardised device‐based assessments.
ABSTRACT Background Gait alterations and biomechanical changes associated with diabetic peripheral polyneuropathy have been described in the literature, but the available evidence remains fragmented. It does not provide a comprehensive overview of how the reported biomechanical patterns differ across clinical stages of the Neuropathic Diabetic Foot (NDF). Mapping these patterns may support an improved understanding of the biomechanical mechanisms underlying increased ulceration risk. Aim This scoping review aims to explore and synthesise the existing literature on changes in gait and foot biomechanics in people with diabetes in association with Diabetic Peripheral Neuropathy (DPN) and across its reported clinical stages. Methods The scoping review was conducted in accordance with the JBI methodology for scoping reviews and in line with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses extension for Scoping Reviews (PRISMA‐ScR). The population included adults with diabetes and peripheral neuropathy, without active foot ulceration, who were managed in community or outpatient settings. The concept of interest is gait and foot‐biomechanical alterations associated with diabetic neuropathy in clinical and biomechanical assessment contexts. A comprehensive search was conducted in PubMed, EMBASE, CINAHL, PEDro, and the Cochrane Library, complemented by grey literature sources including the Trip Medical Database, NICE, and the Guidelines International Network (GIN). Studies published within the last 11 years were considered (2014/12–2026/04). Data were charted and synthesised using a descriptive and narrative approach. Results From 2044 initial records, 44 sources met the eligibility criteria. An updated search conducted in April 2026 identified 6 additional eligible sources, resulting in 50 included sources. The evidence mapped across three principal themes: gait and lower‐limb kinematic alterations, changes in plantar loading and joint kinetics, and structural or functional changes of the foot. No included study directly evaluated whether the identified biomechanical alterations predicted the subsequent development of Charcot neuro‐osteoarthropathy. Conclusions To our knowledge, this is the first scoping review to map structural, kinematic, kinetic, and plantar‐loading findings within an integrated biomechanical framework of the neuropathic diabetic foot. Because the evidence was predominantly cross‐sectional, the proposed relationships should be interpreted as a conceptual synthesis rather than a demonstrated longitudinal progression. These findings highlight the need for longitudinal studies to investigate the temporal evolution of biomechanical alterations in the neuropathic diabetic foot.
ABSTRACT Type 1 diabetes (T1D) in adults is characterised by a less aggressive disease course than in children. Most patients retain preserved C‐peptide (> 02 nmol/L) and some of them benefit from a protracted phase without the need for insulin. Here, we propose a hypothesis‐generating therapeutic paradigm with once‐weekly basal insulin combined with an SGLT2 inhibitor (SGLT2is) as initial therapy in T1D patients with preserved C‐peptide. Once‐weekly basal insulin, approved in Europe and now also in the US, confirm comparable HbA1c reductions to insulin degludec or glargine, albeit always alongside prandial insulin. SGLT2is, approved as adjuncts in T1D in select regions, can control prandial peaks without boluses. No trials have tested the combination of weekly insulin with SGLT2is in adult T1D patients. Nonetheless, the rationale is robust especially in adults with C‐peptide > 0·2 nmol/L. In this respect, we urge proof‐of‐concept trials of 12‐months randomised studies in adults ≥ 18 years, to evaluate this combination.